<DOC>
	<DOCNO>NCT00360230</DOCNO>
	<brief_summary>This study investigate safety immunogenicity 2 candidate malaria vaccine administer accord 3 different vaccination schedule 5 17 month old Ghanaian child . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Partially-blind ( Observer-blind ) Study Safety Immunogenicity Two Malaria Vaccines Ghanaian Children</brief_title>
	<detailed_description>This study conduct partially blind fashion : observer-blind vaccine administer , open vaccination schedule . One group child 0 , 1 , 2-schedule receive Rabies vaccine control . One group schedule receive RTS , S/AS02D experimental vaccine active comparator .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female child 5 month 17 month age time first vaccination . Written oral , sign thumbprinted witness informed consent obtain parent ( ) /guardian ( ) child . Subjects investigator believe parents/guardians comply requirement protocol . Proof child receive full 3dose regimen license Hepatitis B vaccine infancy . Acute disease time enrolment . Serious acute chronic illness determine clinical physical examination laboratory screen test . Laboratory screen test haemoglobin , total white cell count , platelet , ALT creatinine acceptable limit . Planned administration/administration vaccine ( scope study ) within 30 day first dose vaccine ( ) exception tetanus toxoid schedule Yellow fever Measles vaccine . Use investigational nonregistered drug vaccine study vaccine within 30 day precede first dose study vaccine , plan use study period . Administration immunoglobulins , blood transfusion blood product within three month precede first dose study vaccine plan administration study period . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Simultaneous participation clinical trial ; Previous participation malaria vaccine trial ; Any twin History allergic reaction ( significant IgEmediated event ) anaphylaxis previous immunization . History allergic disease reaction likely exacerbate component vaccine . Any finding investigator feel would increase risk adverse outcome participation trial .</criteria>
	<gender>All</gender>
	<minimum_age>5 Months</minimum_age>
	<maximum_age>17 Months</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Plasmodium falciparum</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Prophylaxis Plasmodium falciparum malaria</keyword>
</DOC>